Physician profile
Jameson A Estes
NPI 1265567796
$9,257.15
in general payments reported to CMS, 2019-2025
58 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,649 · 2020: $1,399 · 2021: $1,161 · 2022: $1,449 · 2023: $1,354 · 2024: $1,022 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,598.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,101.92 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,010.26 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $799.03 | 2020-2025 | |
| Glaxosmithkline, LLC. | $602.53 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $588.22 | 2019-2025 | Veozah |
| Pfizer INC. | $447.75 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $436.73 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $381.03 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $329.11 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $312.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $265.24 | 2019-2025 | Repatha, Otezla, Repatha |
| Upsher-Smith Laboratories LLC | $217.61 | 2020-2022 | |
| Amarin Pharma, INC. | $183.66 | 2019-2021 | |
| Allergan, INC. | $180.45 | 2019-2020 | |
| Eisai INC. | $146.75 | 2020-2022 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jameson Estes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.